-+ 0.00%
-+ 0.00%
-+ 0.00%

Freedom Capital Markets Downgrades AtriCure to Hold, Raises Price Target to $57

Benzinga·10/02/2026 11:52:14
語音播報
Freedom Capital Markets analyst Keith Hinton downgrades AtriCure (NASDAQ:ATRC) from Buy to Hold and raises the price target from $43 to $57.